• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·S. Africa·Healthcare·APN.JO
Share

Aspen Pharmacare Holdings Limited Stocks

ZAC 14333Last Updated 12.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

ZAC 38.76M

ZAC 14333
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aspen Pharmacare Holdings Limited is a global pharmaceutical entity that develops, manufactures, and distributes a wide array of specialized and branded medicinal products. The company operates through two primary segments: Commercial Pharmaceuticals and Manufacturing. Its diverse product portfolio encompasses essential anesthetic agents, such as general anesthetics, muscle relaxants, and topical preparations. Aspen also provides a comprehensive suite of thrombosis treatments, including various injectable anticoagulants like low molecular weight heparins, Xa inhibitors, and other heparin derivatives. Beyond these, the firm markets numerous regional consumer, prescription, and over-the-counter brands, such as Circadin for sleep, Foxair for respiratory ailments, Maltofer as an iron supplement, Mybulen for pain management, and Zyloric for gout. Additionally, Aspen produces active pharmaceutical ingredients and finished dose form products for other companies. Established in 1850, the company's headquarters are located in Durban, South Africa.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of APN.JO is 16065 and suggests 11% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026